J&J faces trial in $1B Risperdal influence case

A Texas jury is set to consider allegations that Johnson & Johnson's Janssen unit used false advertising, grants, junkets and other perks to persuade state officials to give its Risperdal antipsychotic drug preferential treatment in a protocol for treating psychiatric disorders. The company faces a potential $1 billion in liability. Report | Article